| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000024570 |
| Receipt No. | R000028273 |
| Scientific Title | A study for the effect of the intake of a plant extracts containing drink on skin conditions and vascular functions. |
| Date of disclosure of the study information | 2016/10/29 |
| Last modified on | 2019/07/30 (Ver. 6) |
| Basic information | ||
| Public title | A study for the effect of the intake of a plant extracts containing drink on skin conditions and vascular functions. | |
| Acronym | A study for the effect of the intake of a plant extracts containing drink on skin conditions and vascular functions. | |
| Scientific Title | A study for the effect of the intake of a plant extracts containing drink on skin conditions and vascular functions. | |
| Scientific Title:Acronym | A study for the effect of the intake of a plant extracts containing drink on skin conditions and vascular functions. | |
| Region |
|
|
| Condition | ||
| Condition | Healthy adults | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | The objective of this study is to evaluate the effects of intake of the plant extract containing drink on skin conditions and vascular function. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Measurement of skin condition
(measurement time: 0,4,8weeks after ingestion of the test drink) |
| Key secondary outcomes | Observation of skin texture
Measurement of vascular function (measurement time: 0,4,8weeks after ingestion of the test drink) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | No need to know |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Ingestion of a bottle of placebo drink once a day for 8 weeks. | |
| Interventions/Control_2 | Ingestion of a bottle of test drink once a day for 8 weeks. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Female | |||
| Key inclusion criteria | 1. Healthy female aged from 25 to 59 years old
2. Persons who have felt mental stress and fatigue. 3. Persons who have dry skin. 4. Menstrual cycle is stable. 5. BMI is from 18.5 to 25.0 6. Person who drink to two cups of coffee per day. |
|||
| Key exclusion criteria | 1. Persons who are outpatients or were treated by doctor recently.
2. Persons who are pregnant or lactating, or planned to become pregnant in the near future. 3. Persons who have problems with electrocardiogram test such as arrhythmia. 4. Persons who take medicine (example: sleeping pills, anti-allergic drugs, hormone drugs, laxative, antiflatulent, and other medicines) 5. Persons who routinely take quasi-drugs and healthy foods. 6. Persons who have severe allergic disease as pollen allergy, rhinitis, atopic dermatitis. 7. Persons who have possibilities for emerging allergy to foods and cosmetics. 8. Current smoker 9. Persons who have received a cosmetic medicine (cosmetic surgery, injection of collagen, laser treatment, etc.) 10. Persons whose blood pressure is 140mmHg or more. 11. Persons who are participate in the other clinical studies 12. Patients with vascular function disorder. 13. Persons who are judged as unsuitable for the study by the investigator for other reason. |
|||
| Target sample size | 100 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Yaesu Nihonbashi Skin Clinic | ||||||
| Division name | Director | ||||||
| Zip code | |||||||
| Address | Yaesu Kagawa Building 3F, 1-5-17 Yaesu, Chuo-ku, Tokyo | ||||||
| TEL | 03-6202-1200 | ||||||
| yanosyo-tky@umin.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | 701 Research, Inc. | ||||||
| Division name | Manager | ||||||
| Zip code | |||||||
| Address | Grand Maison Sendagi Ichiban-kan 2F, 4-1-16, Sendagi Bunkyo-ku, Tokyo 113-0022 Japan | ||||||
| TEL | 03-5832-9875 | ||||||
| Homepage URL | |||||||
| 701@above-ac.com | |||||||
| Sponsor | |
| Institute | 701 Research, Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Kao Corporation |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | |
| Address | |
| Tel | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 株式会社セブンオーワンリサーチ(東京都) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| Result | |||||||
| URL related to results and publications | |||||||
| Number of participants that the trial has enrolled | 108 | ||||||
| Results | Results: After ingesting coffee polyphenols (CPPs), including chlorogenic acids, for 8 weeks, the water holding capacity levels increased on the measured areas of the body. In addition, the increase in transepidermal water loss levels after tape-stripping was suppressed. Furthermore, an improvement of subjective stress symptoms was observed. |
||||||
| Results date posted |
|
||||||
| Results Delayed | |||||||
| Results Delay Reason | |||||||
| Date of the first journal publication of results |
|
||||||
| Baseline Characteristics | |||||||
| Participant flow | |||||||
| Adverse events | |||||||
| Outcome measures | |||||||
| Plan to share IPD | |||||||
| IPD sharing Plan description | |||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB | |||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028273 |